Pfizer’s Center for Therapeutic Innovation and the Alzheimer’s Drug Discovery Foundation announced a collaborative agreement to research and advance the development of small-molecule drugs for Alzheimer’s disease. The duo will invest in research projects in the hopes of finding unique Alzheimer’s drug targets as well as translating novel scientific research into “effective therapeutics for Alzheimer’s disease,” the companies stated. CTI states that its ultimate goal “of each collaborative research project is to identify a drug candidate that can be moved into further clinical testing.”